Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: $7.0 billion (+18%) Comments: Oncology sales were $22.4 billion, up 21%.
High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...
It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results